NCT07171541

Brief Summary

Correlation between optical coherence tomography and multifocal electroretinogram findings with visual acuity in patients with macular dystrophy.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2025

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 27, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

September 12, 2025

Completed
8 days until next milestone

Study Start

First participant enrolled

September 20, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2025

Completed
Last Updated

September 12, 2025

Status Verified

September 1, 2025

Enrollment Period

2 months

First QC Date

August 27, 2025

Last Update Submit

September 8, 2025

Conditions

Macular Dystrophy

Outcome Measures

Primary Outcomes (3)

  • BCVA (best corrected visual acuity)

    BCVA was recorded in 30 eyes of 30 patients with macular dystrophy.

    Day 1/month 3

  • CMT (central macular thickness) μm Central macular thickness measurement using optical coherence tomography

    CMT (central macular thickness) in μm in 30 eyes of 30 patients with macular dystrophy Central macular thickness measurement using optical coherence tomography.

    Day1/month 3

  • mf-ERG amplituide nV/deg2

    mf-ERG amplitude nV/deg² in 30 eyes of 30 patients with macular dystrophy multifocal electroretinogram amplitude measurement using the mf-ERG machine

    Day 1/month 6

Interventions

OCT ,mFERG,VA testDIAGNOSTIC_TEST

retinal photography by OCT, VA measurement, and mfERG test

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients diagnosed with macular dystrophy during the period of the study

You may qualify if:

  • All patients diagnosed with macular dystrophy in Tiba Eye Centre, Egypt, Assiut, during the period of the study

You may not qualify if:

  • The patients diagnosed with macular dystrophy refuse to contribute to the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.principle investigators/ Lecture of ophthalmology ,faculty of medicine , New Valley University

Study Record Dates

First Submitted

August 27, 2025

First Posted

September 12, 2025

Study Start

September 20, 2025

Primary Completion

November 20, 2025

Study Completion

December 20, 2025

Last Updated

September 12, 2025

Record last verified: 2025-09